CoChat

The DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.

Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS

Costabel, Ulrich, Inoue, Yoshikazu, Richeldi, Luca, Collard, Harold R., Tschoepe, Inga, Stowasser, Susanne, Azuma, Arata · 2016 · American Journal of Respiratory and Critical Care Medicine

Abstract

Rationale: In the two replicate, placebo-controlled, 52-week, phase III INPULSIS trials, nintedanib 150 mg twice daily significantly reduced the annual rate of decline in FVC, the primary endpoint, in subjects with idiopathic pulmonary fibrosis (IPF). It is unknown if this effect was uniform across all subjects treated with nintedanib. Objectives: To investigate the potential association of demographic and clinical variables with the effect of nintedanib in subjects with IPF. Methods: Subgroup analyses of pooled data from the INPULSIS trials were prespecified. Subgroups were analyzed by sex, age (<65, ≥65 yr), race (white, Asian), baseline FVC percentage predicted (≤70%, >70%), baseline St. George’s Respiratory Questionnaire (SGRQ) total score (≤40, >40), smoking status (never, ex/current), systemic corticosteroid use (yes/no), and bronchodilator use (yes/no). Measurements and Main Results: A total of 1,061 subjects were treated (nintedanib n = 638, placebo n = 423). There was no statistically significant difference in the effect of nintedanib for the primary endpoint or the key secondary endpoints of change from baseline in SGRQ total score or time to first acute exacerbation in any subgroup. Treatment effects for the key secondary endpoints seemed more pronounced in subjects with baseline FVC ≤70% predicted, because the majority of acute exacerbations and a greater deterioration in SGRQ total score occurred in placebo-treated subjects in this subgroup. Conclusions: Pooled data from the INPULSIS trials support a consistent effect of nintedanib across a range of IPF phenotypes by slowing disease progression across a number of prespecified subgroups.

Overview

Integrity signals

Registry

Crossref · 10.1164/rccm.201503-0562oc

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 21 references

Research works printed but not linked: 3

  1. Costabel, 2014, Effect of baseline FVC on decline in lung function with nintedanib: results from the INPULSIS trials [abstract], Eur Respir J, 44, A1907
  2. Taniguchi, 2014, Subgroup analysis of Asian patients in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis [abstract], Respirology, 19, 1
  3. Raghu, 2015, Consistent effect of nintedanib on decline in FVC in patients across subgroups based on HRCT diagnostic criteria: results from the INPULSIS trials in IPF [abstract], Am J Respir Crit Care Med, 191, A1022

Cited by

See all 288

Metadata

Authors
Costabel, U., Inoue, Y., Richeldi, L., Collard, H. R., Tschoepe, I., Stowasser, S., & Azuma, A.
Affiliations
  • Ruhrlandklinik (DE)
  • NHO Kinki Chuo Chest Medical Center (JP)
  • National Institute for Health and Care Research (GB)
  • University of California, San Francisco (US)
  • Boehringer Ingelheim (France) (FR)
  • Boehringer Ingelheim (Germany) (DE)
  • Nippon Medical School (JP)
Corresponding author
Costabel, Ulrich
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2016-01
Volume
193
Issue
2
Pages
178-185
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W1757222072
Cited by
280
References
21
Citations by year
2026: 11 · 2025: 12 · 2024: 20 · 2023: 18 · 2022: 19 · 2021: 12 · 2020: 40 · 2019: 35 · 2018: 35 · 2017: 50 · 2016: 26
FWCI
29.79
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Respiratory and Critical Care Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • ePrints Soton (University of Southampton) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords
nintedanib, idiopathic pulmonary fibrosis, INPULSIS trials, subgroup analysis, treatment effect heterogeneity, forced vital capacity decline, St George's Respiratory Questionnaire, acute exacerbation, sex differences, age differences, race, smoking status, systemic corticosteroids, bronchodilator use, disease progression
MeSH terms
Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Vital Capacity, Disease Progression, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS. https://app.cochat.ai/papers/10.1164/rccm.201503-0562oc
The paper
Costabel, U., Inoue, Y., Richeldi, L., Collard, H. R., Tschoepe, I., Stowasser, S., & Azuma, A. (2016). Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201503-0562oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.